VB Spine secures Augmedics CT-Fluoro spine rights
VB Spine has signed a definitive agreement to acquire the exclusive rights to Augmedics’ CT-to-fluoroscopy technology for spinal applications, extending its position in augmented reality navigation systems.
The New York-based company said the agreement builds on its April acquisition of the exclusive rights to the Augmedics xvision Spine System platform. The latest deal adds another technology associated with the xvision name and broadens VB Spine’s rights in the spine navigation field.
Financial terms were not disclosed. The transaction remains subject to standard closing conditions and regulatory requirements, and the company did not offer a timetable for completion.
According to the companies, CT-Fluoro technology is designed to allow surgeons to register a patient’s preoperative CT scan using standard fluoroscopic imaging. That approach differs from methods that rely on intraoperative CT or 3D imaging systems. The companies said the technology is intended to give surgeons greater flexibility in operating room workflows and to broaden access to augmented reality navigation in facilities without high-end imaging equipment.
VB Spine said the technology will be added to its products for spine procedures after the transaction closes. The company also said the acquisition fits within a wider plan to expand the xvision ecosystem and reduce the imaging requirements associated with spine surgery. In the announcement, the company said the technology may remove the need for intraoperative CT or 3D imaging in some procedures.
The announcement included a statement from Marc Viscogliosi, co-CEO of VB Spine, speaking on behalf of fellow co-CEOs Anthony and John Viscogliosi. The company said the addition of CT-Fluoro technology for spine applications would give surgeons more flexibility in how they use navigation. That statement was presented as part of the transaction announcement rather than as an independently verified finding.
Augmedics developed the xvision platform before transferring the exclusive rights to VB Spine earlier this year. The new agreement extends that relationship by adding CT-Fluoro technology for spine use to VB Spine’s rights. The companies did not say whether the two technologies would be combined in a single product or offered separately after closing.
The announcement did not contain a closing date or any detail on when commercial availability might begin under VB Spine ownership. It also did not set out any launch timetable for the CT-Fluoro technology once the transaction is complete.
VB Spine said the acquisition is part of a broader effort to expand access to navigation technology by reducing imaging requirements in certain spine surgery settings. The company said the technology is aimed at facilities without access to state-of-the-art imaging equipment, and it linked the deal to its wider xvision strategy.
The agreement adds to a series of steps taken by VB Spine since its earlier April transaction involving the xvision Spine System platform. With the latest rights acquisition, the company said it plans to broaden its offerings in spine procedures once the transaction clears the remaining closing and regulatory steps.
